Actuate Therapeutics (NASDAQ:ACTU) Downgraded to Sell Rating by Wall Street Zen

Actuate Therapeutics (NASDAQ:ACTU) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

A number of other equities research analysts also recently weighed in on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Actuate Therapeutics in a report on Monday, December 29th. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Actuate Therapeutics in a research report on Wednesday, November 19th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $20.33.

Actuate Therapeutics Price Performance

NASDAQ:ACTU opened at $2.86 on Friday. The company has a market cap of $66.47 million, a P/E ratio of -3.29 and a beta of 0.10. The firm’s fifty day moving average price is $4.88 and its two-hundred day moving average price is $6.35. Actuate Therapeutics has a one year low of $2.73 and a one year high of $11.99.

Insider Activity at Actuate Therapeutics

In other news, Director Todd S. Thomson sold 280,000 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $5.80, for a total transaction of $1,624,000.00. Following the completion of the sale, the director owned 904,795 shares in the company, valued at $5,247,811. The trade was a 23.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 69.34% of the stock is currently owned by corporate insiders.

Institutional Trading of Actuate Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. ABS Direct Equity Fund LLC bought a new position in Actuate Therapeutics during the 4th quarter valued at $40,000. Deutsche Bank AG raised its holdings in shares of Actuate Therapeutics by 640.0% in the fourth quarter. Deutsche Bank AG now owns 9,309 shares of the company’s stock valued at $57,000 after purchasing an additional 8,051 shares during the last quarter. Sfmg LLC lifted its position in shares of Actuate Therapeutics by 32.3% during the 2nd quarter. Sfmg LLC now owns 14,550 shares of the company’s stock worth $89,000 after buying an additional 3,550 shares in the last quarter. Barclays PLC grew its stake in Actuate Therapeutics by 68.6% in the 4th quarter. Barclays PLC now owns 14,946 shares of the company’s stock valued at $91,000 after purchasing an additional 6,081 shares during the period. Finally, Bank of America Corp DE grew its stake in Actuate Therapeutics by 61,068.0% in the 2nd quarter. Bank of America Corp DE now owns 15,292 shares of the company’s stock valued at $93,000 after purchasing an additional 15,267 shares during the period.

Actuate Therapeutics Company Profile

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.